The NDA submission triggers a 60-day filing acceptance review by the FDA; if accepted, a PDUFA target action date will be set approximately 6-8 months later. The confirmatory Phase 3 RESTORE-ALS study timeline and any potential priority review designation will be key catalysts to monitor.
Price Chart
Executive Summary
Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS), based on neurofilament light chain biomarker data and clinical outcomes. This is a pivotal regulatory milestone for a clinical-stage biotech with no approved products, and the outcome will determine the company's near-term viability.
Key Facts
- NDA submitted to FDA seeking accelerated approval of CNM-Au8 for ALS
- Submission based on neurofilament light chain biomarker data and clinical outcomes
- Company is a clinical-stage biotech with no currently marketed products
- Confirmatory Phase 3 RESTORE-ALS study is planned
- CNM-Au8 is an investigational first-in-class therapy targeting mitochondrial function and the NAD pathway
Financial Impact
Not stated in the release; no financial figures provided
Risk Factors
- FDA may reject the NDA or require additional clinical data before granting accelerated approval
- Accelerated approval pathway for ALS is uncertain; FDA may require a traditional approval standard
- Company has no approved products and will need additional funding to complete confirmatory studies and commercialization
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383356 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $3.73 | awaiting T+20 | — | $3.84 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $3.29 | awaiting T+20 | — | $3.84 (+16.72%) |
Oct 19, 2026 7d ago | Press Release | $3.29 | awaiting T+20 | — | $3.84 (+16.72%) |
Oct 13, 2026 13d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.84 (+13.27%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.84 (+7.47%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.84 (+0.52%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.84 (−7.25%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.84 (−7.25%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.84 (−25.58%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.84 (−45.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers